Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.
Blimark C et al. Haematologica. 2014 Oct 24. pii: haematol.2014.107714. [Epub ahead of print].
Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy.
Li J et al. Cell Biochem Biophys. 2014 Oct 25. [Epub ahead of print].
Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report.
Aldave AP et al. J Med Case Rep. 2014 Oct 23;8(1):353. [Epub ahead of print].
Pseudohypobicarbonatemia in a patient with a kappa IgA monoclonal gammapathy.
Lazzouni I et al. Ann Biol Clin (Paris). 2014 Oct 1;72(5):599-601.
Evolving Treatments in Multiple Myeloma Patients with Renal Failure.
Gozzetti A. Rev Recent Clin Trials. 2014 Oct 20. [Epub ahead of print].
Reconstruction of multiple myeloma lesions around the pelvis and acetabulum.
Sakellariou VI et al. Eur J Orthop Surg Traumatol. 2014 Oct 19. [Epub ahead of print].
Chemotherapy-induced peripheral neuropathies in hematological malignancies.
Jongen JL et al. J Neurooncol. 2014 Oct 19. [Epub ahead of print].
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Gabbert TI et al. J Cancer Res Clin Oncol. 2014 Oct 16. [Epub ahead of print].
Bone-targeted therapies for cancer patients and bone cell biology: where do we stand?
Berenson JR. Curr Opin Support Palliat Care. 2014 Oct 14. [Epub ahead of print].
Unique morphology of intratubular light chain casts in multiple myeloma: The amyloid cast nephropathy.
Sharma A et al. Indian J Pathol Microbiol. 2014 Oct-Dec;57(4):629-31. doi: 10.4103/0377-4929.142712.
Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies.
Teh BW et al. Haematologica. 2014 Oct 10. pii: haematol.2014.114025. [Epub ahead of print].
Thalidomide-prednisone maintenance following autologous stem cell transplant for Multiple Myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
Kovacs MJ et al. Br J Haematol. 2014 Oct 10. doi: 10.1111/bjh.13176. [Epub ahead of print].
Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.
Pawlyn C et al. Blood. 2014 Oct 9;124(15):2467-8. doi: 10.1182/blood-2014-06-583302.
Demonstration of the cause of acute renal failure in a case of IgD multiple myeloma.
Lescoat A et al. Br J Haematol. 2014 Oct 9. doi: 10.1111/bjh.13177. [Epub ahead of print].
Light chain crystalline kidney disease: diagnostic urine microscopy as the “liquid kidney biopsy”
Luciano RL et al. Clin Nephrol. 2014 Oct 8. [Epub ahead of print].
Paraproteinemic neuropathies.
Raheja D et al. Muscle Nerve. 2014 Oct 6. doi: 10.1002/mus.24471. [Epub ahead of print].
Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.
St Bernard R et al. Bone Marrow Transplant. 2014 Oct 6. doi: 10.1038/bmt.2014.226. [Epub ahead of print].
Therapy-Related Myelodysplastic Syndrome/Acute Leukemia After Multiple Myeloma in the Era of Novel Agents.
Gertz MA et al. Leuk Lymphoma. 2014 Oct 6:1-16. [Epub ahead of print].
Cutaneous presentation of an aggressive plasmablastic neoplasm indiscriminate between lymphoma and myeloma.
Johnston AC et al. Ann Hematol. 2014 Oct 5. [Epub ahead of print].
Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis.
Herrera GA. Arch Pathol Lab Med. 2014 Oct;138(10):1365-80. doi: 10.5858/arpa.2013-0493-OA.
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L et al. BMC Nephrol. 2014 Sep 30;15(1):156. doi: 10.1186/1471-2369-15-156.